Axitinib as first-line therapy in metastatic renal cell carcinoma

Masahiro Nozawa, Hirotsugu Uemura

Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan

Correspondence to: Masahiro Nozawa, MD, PhD. Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan. Email: nozawa06@med.kindai.ac.jp.

Abstract: Axitinib is a highly potent and selective VEGF receptor inhibitor. Previous trials suggested a significant advantage of axitinib versus sorafenib in progression-free survival (PFS) of patients with metastatic renal cell carcinoma (RCC) treated with prior cytokine therapy. Recently an important negative study was reported, which evaluated the PFS with axitinib and with sorafenib in treatment-naïve metastatic RCC. This study was underpowered but conveyed an important message on the limit of current VEGF signal targeted drugs as a first-line therapy. In the future, more emphasis should be put on arrangement of dosing and scheduling of drugs already approved as well as development of new agents targeting novel molecules in this disease.

Keywords: Axitinib; first-line therapy; performance status; renal cell carcinoma (RCC); sorafenib

Submitted May 31, 2014. Accepted for publication Jun 03, 2014.

doi: 10.3978/j.issn.2218-676X.2014.06.01

View this article at: http://dx.doi.org/10.3978/j.issn.2218-676X.2014.06.01

Axitinib is a potent and selective second-generation VEGFR inhibitor (1). A pivotal phase III trial, named AXIS, revealed the superiority of axitinib over sorafenib in terms of progression-free survival (PFS) in advanced renal cell carcinoma (RCC) after failure of one previous systemic therapy (2). In the AXIX trial, median PFS in cytokine-refractory patients was 12.1 months with axitinib versus 6.5 months with sorafenib. However, Hutson et al. recently reported a negative result from a relatively small-numbered phase III trial in which 288 treatment-naïve patients with metastatic RCC were randomly assigned to axitinib and sorafenib (3). The trial was designed with the prediction of 4.3 months improvement in median PFS in axitinib over sorafenib. The design looked reasonable because previous trials showed median PFS of 12.1 to 13.7 months with axitinib in cytokine-refractory disease, on the other hand, median PFS of 5.5 to 6.5 months with sorafenib in cytokine-refractory or treatment-naïve patients (2,4-6). As a result, median PFS with sorafenib was not surprising, whereas median PFS with axitinib was disappointing. There was no significant difference in median PFS between patients treated with axitinib and sorafenib in this trial [10.1 months (95% CI, 7.2-12.1) vs. 6.5 months (95% CI, 4.7-8.3)], respectively; stratified hazard ratio 0.77 (95% CI, 0.56-1.05) (3). One of the reasons for this result may be that more patients without previous nephrectomy were included in the axitinib group (15%) than in the sorafenib group (10%). Indeed, a subgroup analysis of patients with previous nephrectomy showed that median PFS was significantly improved with axitinib versus sorafenib. However, it was noteworthy that median PFS in patients with ECOG performance status 0 treated with tivozanib had significantly longer median PFS than those with sorafenib (14.8 vs. 9.1 months, respectively; P=0.004), however, no difference was observed between the tivozanib group and the sorafenib in patients with ECOG performance status 1 (9.1 vs. 9.0 months, respectively; P=0.59). Median PFS with sorafenib was similar in patients with ECOG performance status 0 and 1 in both TIVO-1 and this axitinib trial. Such
steady treatment effect of sorafenib regardless of performance status can be advantage over other targeted agents for advanced RCC. In contrast, the effect of axitinib and tivozanib may be affected by patient’s performance status. Axitinib and tivozanib have a similar target profile that is relatively specific to VEGFR-1, 2, and 3 (Table 1) and this characteristics common between these two agents may have contributed to the trend as to treatment effect and performance status.

In this axitinib study, both agents were given according to their approved labeling, such that dose increases were allowed with axitinib, but not with sorafenib. This difference in dose increase capability may have made a contribution to the difference in objective response rates between axitinib and sorafenib [32% vs. 15%, respectively; risk ratio 2.21 (95% CI, 1.31–3.75)], as well as to the rates of serious adverse events (34% vs. 25%, respectively). All major adverse events in all grades but plantar erythrodysesthesia and rash were also more common with axitinib versus sorafenib. Disease progression was the most common cause of death in both groups (86% in axitinib and 97% in sorafenib), however 14% of patients in the axitinib group died of other reasons though the detail was not described except one treatment-related cardiac arrest.

Median duration of response was 14.7 months with axitinib and 14.3 months with sorafenib, that means there was no difference in the time to evolution of resistance against each drug.

Overall, this axitinib study was underpowered for its primary endpoint and it is questionable why sorafenib was chosen as the control in first-line setting although the authors explained the reason as sorafenib was available in the regions where the trial was conducted. Sunitinib or pazopanib definitely should be used as a comparator in the treatment-naïve setting. However, what is suggested from this study is that PFS with axitinib as first-line therapy will not demonstrably overwhelm that with sunitinib or pazopanib. The PFS of tivozanib, another highly potent and selective VEGFR inhibitor, was also similar with these three drugs based on TIVO-1 trial. It suggests that median PFS with VEGF signal-targeted drugs is around 10 months in first-line setting. So another trial with a larger sample size of axitinib in first-line setting, if planned, will not be intriguing. In the future, development of absolutely novel targeted therapy for this disease is highly desired. Combination of a new agent and an existing drug can be also interesting.

Although PFS is the most commonly used surrogate endpoint for clinical trials in metastatic RCC, the correlation of PFS and overall survival (OS) still remains unclear. Recent phase III trials, including INTORSECT and TIVO-1, also showed unique PFS and OS data. The INTORSECT trial, a head-to-head phase III trial comparing temsirolimus and sorafenib in second-line therapy, showed that PFS was slightly longer but not statistically significant in patients treated with temsirolimus, while OS was significantly longer in those treated with sorafenib (12). The TIVO-1 trial showed that PFS was significantly longer in patients treated with tivozanib, while OS was slightly longer but not significantly in those treated with sorafenib (7). In the AXIS trial, the median PFS was significantly prolonged in the axitinib group compared with the sorafenib group, however, there was no significant difference in the median OS between groups (13). PFS may not be an appropriate surrogate endpoint for OS when comparing those drugs in this disease. The subsequent therapy which may affect improving OS should also be taken into consideration. Devising a way to use agents already approved, for example the cyclic treatment strategy were propounded (14), should be moved forward in order to improve survival of patients with metastatic RCC.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References

1. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-


Cite this article as: Nozawa M, Uemura H. Axitinib as first-line therapy in metastatic renal cell carcinoma. Transl Cancer Res 2014;3(6):555-557. doi: 10.3978/j.issn.2218-676X.2014.06.01